Targeting Human Kallikrein 2 in Prostate Cancer

H&O What is human kallikrein 2 (KLK2), and what makes it a good target in prostate cancer? MS KLK2 is a membrane-associated protease that is involved […]

The Addition of PARP Inhibition to Androgen Receptor Pathway Inhibition in Metastatic Hormone-Sensitive Prostate Cancer

H&O What was the rationale for conducting the AMPLITUDE trial?1 GA We were trying to solve 2 problems. First, although 30% of patients who are started […]

The Use of PSMA PET/CT Imaging as an Endpoint in Clinical Trials of Prostate Cancer

H&O In what clinical situations is the use of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) imaging well established? MM There are 3 approved […]

Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

H&O Could you describe the ENZA-p trial that you and your colleagues conducted? LE ENZA-p was a randomized phase 2 trial that took place at 15 […]

The Addition of Darolutamide to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer

H&O What was the impetus for the ARANOTE trial? FS The ARANOTE trial1 was a follow-up to 2 other large phase 3 studies that looked at […]

PARP Inhibition in HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

H&O What role do mutations in homologous recombination repair (HRR) genes play in metastatic castration-resistant prostate cancer (mCRPC)? TD We have recently come to realize that […]

New Cell Surface Targets in Prostate Cancer

H&O Could you provide a brief overview of cell surface targets in cancer treatment? AJA Cell surface targets are very accessible and engageable, and therapies based […]

Incorporating PSMA PET Imaging Into the Treatment Plan for Newly Diagnosed and Recurrent Prostate Cancer

H&O What are the advantages of prostate-specific membrane antigen positron emission tomography (PSMA PET) over conventional imaging for prostate cancer? NS Conventional imaging, which has been […]

Targeted Therapy in Prostate Cancer: Beyond PSMA

H&O What are the limitations of prostate-specific membrane antigen (PSMA)–targeted therapy in prostate cancer? MM PSMA is a very good target in prostate cancer, but not […]

Management of Oligometastatic Hormone-Sensitive Prostate Cancer

H&O How is oligometastatic defined in the context of hormone-sensitive prostate cancer (HSPC)? PT We used to make a binary distinction between localized HSPC, which is […]

Biomarkers and Novel PET Imaging to Detect Neuroendocrine Prostate Cancer

H&O What is neuroendocrine prostate cancer (NEPC), and how common is it? RA NEPC is an aggressive histologic subtype of prostate cancer. The de novo form […]

Overcoming Immune Evasion in Advanced Prostate Cancer

H&O Why do some patients with prostate cancer respond to immune checkpoint inhibitors (ICIs), whereas others do not? AA Several clinical trials with ICIs, either alone […]

More Highlights in Prostate Cancer From the 2023 American Society of Clinical Oncology Annual Meeting

June 2-6, 2023 • Chicago, Illinois and Virtual Last month, Clinical Advances in Hematology & Oncology highlighted the PEACE-1 trial, the TALAPRO-2 study, and research on […]

Predictive Biomarkers in Advanced Prostate Cancer

H&O What is the difference between a prognostic biomarker and a predictive biomarker? AA Prognostic biomarkers estimate the natural history of a disease, or in other […]

The Use of AI to Identify Predictive, Pathology-Based Biomarkers in Men With Prostate Cancer

H&O How is artificial intelligence (AI) defined in the context of cancer biomarkers, including predictive biomarkers? DS AI is a very general term, of course, that […]

When to Use Somatic Tumor Testing in Prostate Cancer

H&O Which patients with prostate cancer are eligible for somatic tumor testing? TF To begin with, we should be clear about some definitions. Somatic tumor testing […]

Update on Metastatic Hormone-Sensitive Prostate Cancer

H&O How often do men present with de novo metastatic prostate cancer? KC In places where we do a lot of screening, such as the United […]

Special Concerns for Survivors of Prostate Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Andrew C. Peterson, MD Professor of Urologic Surgery Duke University School of Medicine Durham, […]

The Timing of Radium-223 Therapy in Castration-Resistant Prostate Cancer

Clinical Advances in Hematology & Oncology Volume 13, Issue 9, September 2015 Oliver Sartor, MD LaBorde Professor for Cancer Research Medical Director Tulane Cancer Center Departments of […]